Tyr494
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr494  -  TTYH2 (human)

Site Information
LFGRNPRyENVPLIG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 454113
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:
brain cancer ( 1 ) , glioblastoma ( 1 ) , glioma ( 1 ) , colorectal cancer ( 3 ) , colorectal carcinoma ( 3 ) , leukemia ( 4 ) , T cell leukemia ( 4 ) , non-small cell lung cancer ( 2 ) , non-small cell lung adenocarcinoma ( 2 )
Relevant cell line - cell type - tissue:

References 

1

Johnson H, White FM (2014) Quantitative analysis of signaling networks across differentially embedded tumors highlights interpatient heterogeneity in human glioblastoma. J Proteome Res 13, 4581-93
24927040   Curated Info

2

Rikova K (2013) CST Curation Set: 18449; Year: 2012; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954
Curated Info

3

Mulhern D (2012) CST Curation Set: 13331; Year: 2012; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

4

Osinalde N, et al. (2011) Interleukin-2 signaling pathway analysis by quantitative phosphoproteomics. J Proteomics 75, 177-91
21722762   Curated Info